Per Matsson
Thermo Fisher Scientific

The aim of this project is to introduce, assess and refine a new application for individualised prostate cancer risk, the Stockholm3 Risk Score. Compared to the current clinical test, Stockholm3 Risk Score finds more aggressive cancers and reduces the number of unnecessary biopsies by more than 50%. 

The Stockholm3 Risk Score was developed in a joint clinical research programme between TFS, a Swedish HCP and KI. It is designed to be more accurate than existing prostate cancer screening methods by combining genetic and protein biomarkers with clinical data in a multivariate algorithm.

Benefits of this innovation include lower mortality from prostate cancer and fewer harmful misdiagnoses.


The Stockholm3 Risk Score has been evaluated in 58,000 men and the results have been published in peer reviewed journals. It is now available as a Lab Developed Test (LDT) for clinical use in Sweden, through the Karolinska Hospital Laboratory. Work is currently underway to further develop the Stockholm3 Risk Score to adopt to the different needs of healthcare payers, individual men and big data collection.

A pan-European adoption of the application will be initiated during 2018 and a full technology agnostic product will become available shortly thereafter. Linking the structured data collection to therapy outcome will allow for improved for prostate cancer management.

The end goal is to rapidly reduce the present controversy in prostate cancer diagnostics, improve quality of life and reduce mortality in a cost effective manner. Additionally, a rapid introduction of the STHLM3 Risk Score application will serve as a model for rapid innovation in health care.

Target Group

The target market for an improved prostate cancer diagnostic test include asymptomatic men, health care providers, society as a whole and pharma companies. The global market for prostate cancer products was $29.3 billion in 2012 and is projected to increase to $50.3 billion by 2017. The market for diagnostics and screening alone was $17.4 billion. Factors for this strong growth include the ageing male population and increased demand for treatment and the development and use of new and expensive drugs.

EIT Health partners in this project